Napo Pharmaceuticals, Inc. Terminates Salix Pharmaceuticals, Ltd. for Breach of Agreement for Failure to Commercially Develop Crofelemer

Published: Nov 10, 2011

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (“Napo”) announced today that, on November 4, 2011, it terminated its Collaboration Agreement with Salix Pharmaceuticals, Inc. (“Salix”) dated December 9, 2008 (the “Collaboration Agreement”) to commercially develop its first in class novel drug compound, crofelemer. The compound is a treatment for diarrhea, a life-threatening ailment that impacts millions of people across the world.

Back to news